Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Open accessThe DOI matches its Crossref record; 64 of the 70 references it cites were found in a registry or an index, and 6 are not checked yet; 19 of the 29 sources its claims cite were checked for support.
Abstract
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK
Verified 2026-10-05 · 6 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 3 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Not checked yetcites [2] Routy B, Science 359, 91– 97 (2018). 29097494 source
- Supportedcites [3] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 source
The supplied Abstract passage reports an association between gut microbial composition and clinical response to anti-PD-1 therapy in metastatic melanoma patients. It also reports that transferring responder-associated microbiota improved anti-PD-L1 efficacy in mice, supporting the claim that gut bacteria can modulate response to checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [4] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s concluding passage says the gut microbiome may modulate responses to anti-PD-1 immunotherapy in melanoma patients. The citing sentence states this more broadly and definitively for immune checkpoint blockade in cancer; the paper’s patient findings are limited to melanoma and anti-PD-1 treatment. Page numbers were not provided in our copy. (LLM, conf=0.85)
- Partly supportedcites [5] Frankel AE, Neoplasia 19, 848– 855 (2017). 28923537 PMC5602478 sourceExperimental — accuracy not yet measured
The Introduction reports that gut microbiota affect checkpoint-therapy responses in preclinical mouse models, and the Results find different bacterial species enriched in melanoma patients who responded to treatment. The human findings are associations, however; the paper says the mechanism of immune enhancement by these bacteria in humans remains unknown. Thus it does not establish that gut bacteria modulate treatment response in cancer patients. (LLM, conf=0.84)
- Supportedcites [6] Peters BA, Genome Med 11, 61 (2019). 31597568 PMC6785875 source
The Conclusions state that the pilot study supports the notion that gut microbiota modulate immunotherapy response in melanoma patients. The Background identifies the treatments studied as PD-1 and CTLA-4 checkpoint inhibitors, matching the claim’s reference to immune checkpoint blockade. (LLM, conf=0.91)
- Partly supportedcites [7] Andrews MC, Nat. Med 27, 1432– 1441 (2021). 34239137 PMC11107795 sourceExperimental — accuracy not yet measured
The Main Text reports that several gut bacterial taxa differed between melanoma patients who did and did not respond to combined checkpoint blockade, with related associations in mouse tumor models (page unavailable). This supports a link between gut bacteria and treatment response, but the patient findings are associations; they do not establish that bacteria modulate response in cancer patients generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“given the known impact of these on ICB response (32)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Partly supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 sourceExperimental — accuracy not yet measured
The Key Points report that antibiotics given within 30 days before immune checkpoint inhibitor therapy were associated with a higher risk of disease refractory to treatment. The claim is broader than the finding: the paper reports an observational association for prior antibiotic use, while its Limitations section says concurrent antibiotic use was not associated with response. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“however, this is not unexpected given the known challenges of isolating associations of specific dietary components from other factors known to affect the gut microbiota in observational human cohorts (33, 34).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [33] Klurfeld DM, Am. J. Physiol. Endocrinol. Metab 315, E1087– E1097 (2018). 30130151 PMC6415710 source
The WORKSHOP SUMMARY ('Focus on human studies of the colonic microbiome') states numerous challenges in characterizing diet effects on the human gut microbiome, including poor adherence, inaccurate characterization of dietary intake/composition, and that human observational studies generally point only to associations, with logistical challenges in large cohort studies. The same summary notes that diets high in protein or fat are necessarily low in carbohydrates, 'making it almost impossible to attribute causality to an individual macronutrient,' and lists nondietary factors (stress, exercise, smoking, coffee, personality) plus marked interindividual variation that must be recorded. The table under 'Choice of species depends on question(s) asked.' adds that cross-sectional studies cannot prove causality and that intake recording is relatively inaccurate. Together these support the paraphrase that isolating specific dietary components from other microbiota-affecting factors in observational human cohorts is challenging. (LLM, conf=0.87)
- Not checked yetcites [34] Makki K, Deehan EC, Walter J, Bäckhed F, Cell Host Microbe 23, 705– 715 (2018). 29902436 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given that many of the response-associated bacteria identified in our cohort have known roles in starch degradation and fiber fermentation (25–29)”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [25] Flint HJ, Scott KP, Duncan SH, Louis P, Forano E, Gut Microbes 3, 289– 306 (2012). 22572875 PMC3463488 source
The paper’s Firmicutes sections describe starch utilization by Roseburia and Eubacterium rectale and plant-fiber polysaccharide utilization by Roseburia intestinalis and other gut bacteria (page numbers unavailable). The citation supports the bacteria’s known roles; identifying which bacteria were response-associated in the citing authors’ cohort is the citing authors’ own observation. (LLM, conf=0.86)
- Partly supportedcites [26] den Besten G, J. Lipid Res 54, 2325– 2340 (2013). 23821742 PMC3735932 sourceExperimental — accuracy not yet measured
In “The composition of gut microbiota” (page unavailable), the review identifies Bacteroidetes as fermenters of nondigestible carbohydrates, supporting a general role for gut bacteria in fiber fermentation. It does not identify the citing paper’s response-associated bacteria or establish that many of them degrade starch. (LLM, conf=0.84)
- Partly supportedcites [27] Poeker SA, Sci. Rep 8, 4318 (2018). 29531228 PMC5847601 sourceExperimental — accuracy not yet measured
The Results and Discussion describe bacterial responses to dietary fibers and identify taxa involved in fermenting or degrading them, including inulin-degrading Ruminococcaceae and Prevotella fermenting complex polysaccharides. The paper does not establish a role in starch degradation for these bacteria. Which bacteria were identified in the citing authors’ cohort is their own finding, not a finding attributed to this source. (LLM, conf=0.84)
- Partly supportedcites [28] So D, Am. J. Clin. Nutr 107, 965– 983 (2018). 29757343 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says Bifidobacterium and Lactobacillus utilize prebiotic fibers as substrates and discusses their fermentation preferences, supporting the fiber-fermentation part. The paper does not establish starch-degradation roles for many bacteria; its References list a work on Ruminococcus bromii and resistant-starch degradation, but that does not substantiate the broader claim. (LLM, conf=0.82)
- Supportedcites [29] Desai MS, Cell 167, 1339– 1353. e21 (2016). 27863247 PMC5131798 source
The Results describe testing gut bacteria for growth on dietary-fiber polysaccharides and identifying which bacteria use each carbohydrate. The supplemental figure (Additional information; page unavailable) identifies several species as plant-fiber and starch degraders and depicts short-chain fatty acid production from plant fiber. The cited paper supports those functional roles; the statement that the bacteria were response-associated in the citing authors’ cohort is their own framing. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The observed protective effect of dietary fiber intake in relation to PFS and response remained consistent among the subset of patients treated with anti–PD-1 monotherapy, with the exclusion of patients reporting recent antibiotic use given the known impact of these on ICB response (32) (tables S11 and S12).”
§ Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response > Abstract
What the sources say
- Supportedcites [32] Pinato DJ, JAMA Oncol 5, 1774– 1778 (2019). 31513236 PMC6743060 source
The citation is attached to the rationale for excluding patients with recent antibiotic use, not to the citing authors’ dietary-fiber findings. The Results report that prior antibiotic therapy was associated with poorer response to immune checkpoint inhibitor treatment; the paper distinguishes this from concurrent antibiotic therapy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 1 with their cited sources checked
Create a free account to see all 52 claims and to verify the 10 references still open.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fiber-rich, plant-based diets have the opposite effect, nurturing Bifidobacterium and Lactobacillus, increasing butyrate producers like Roseburia and Eubacterium rectale, and shielding against obesity and insulin resistance via SCFA signaling.15,70,81–83”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies have linked deficient SCFA production to conditions such as graft-versus-host disease and poor responses to cancer immunotherapies, spurring interest in SCFA supplementation or diets to restore microbial balance.15,77,88,146,147”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supporting a potential benefit of microbially produced SCFAs and an adjuvant role of fiber for ICB7,25.”
From Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, correlations have been drawn across cancer indications and geographical sites between the taxonomic composition of the gut (and to some degree tumor) microbiota, and ICI responses in patients with melanoma and other cancers.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, exposures including medications, especially antibiotics and proton pump inhibitors, and diet that shape the microbiota are associated with ICI responses in patient cohorts and preclinical models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [13]
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Research works printed but not linked: 1
- H. Mallick A. Rahnavard L. J. McIver S. Ma Y. Zhang L. H. Nguyen T. L. Tickle G. Weingart B. Ren E. H. Schwager S. Chatterjee K. N. Thompson J. E. Wilkinson A. Subramanian Y. Lu L. Waldron J. N. Paulson E. A. Franzosa H. C. Bravo C. Huttenhower Multivariable Association Discovery in Population-scale Meta-omics Studies. bioRxiv 2021.01.20.427420 [Preprint] (2021). .10.1101/2021.01.20.427420 2021.01.20.427420 · doi:10.1101/2021.01.20.427420
Cited by
Items 201–300 of 967
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Emerging roles of the gut microbiota in cancer immunotherapy
Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139821 · Cited by 34
Vernaci, G. M., Savarino, E. V., Patuzzi, I., Facchin, S., Zingone, F., Massa, D., Faggioni, G., Giarratano, T., Miglietta, F., Griguolo, G., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad060 · Cited by 36
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
Gut microbiota shed new light on the management of immune‐related adverse events
Tan, B., Liu, Y., Tang, H. T., Chen, D., Xu, Y., Chen, M., Li, Y., Wang, M., & Qian, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14626 · Cited by 36
The role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 34
Self-citationThe Role of Artificial Intelligence in Deciphering Diet–Disease Relationships: Case Studies
Cohen, Y., Valdés‐Mas, R., & Elinav, E. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-090535 · Cited by 38
Barrea, L., Verde, L., Annunziata, G., Camajani, E., Caprio, M., Šojat, A. S., Marina, L., Guarnotta, V., Colao, A., & Muscogiuri, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02169-2 · Cited by 35
Gamrath, L., Pedersen, T. B., Møller, M. V., Volmer, L. M., Holst-Christensen, L., Vestermark, L. W., & Donskov, F. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01622-6 · Cited by 30
“Two trials in melanoma patients by Spencer et al. [28] and Pietrzak et al. [39]. indicated that a high intake of plant foods and dietary fiber was positively correlated with a better response to immunotherapy.”
InfluentialMicrobiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
Short-term dietary fiber interventions produce consistent gut microbiome responses across studies
Rodriguez, C. I., Isobe, K., & Martiny, J. B. H. (2024) · mSystems · doi:10.1128/msystems.00133-24 · Cited by 38
Gut microbiota interact with breast cancer therapeutics to modulate efficacy
Arnone, A. A., Ansley, K. C., Heeke, A. L., Howard-McNatt, M. M., & Cook, K. L. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00185-0 · Cited by 44
Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
Huang, M., Zhang, Y., Chen, Z., Yu, X., Luo, S., Peng, X., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107726 · Cited by 34
Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 36
Fennell, D. A., Sekido, Y., Baas, P., Husain, A. N., Fontecedro, A. C., Lim, E. K. S., Opitz, I., Simone, C. B., Brims, F., & Wong, M. C. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00640-3 · Cited by 47
Self-citationDectin-1b activation by arabinoxylans induces trained immunity in human monocyte-derived macrophages
Moerings, B. G. J., van Bergenhenegouwen, J., Furber, M., Abbring, S., Schols, H. A., Witkamp, R. F., Govers, C., & Mes, J. J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.04.071 · Cited by 31
Disentangling the molecular mystery of tumour–microbiota interactions: Microbial metabolites
Duan, Y.-W., Dai, J.-H., Lu, Y.-Q., Qiao, H., & Liu, N. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70093 · Cited by 31
Farias, R. M., Jiang, Y., Levy, E. J., Hwang, C. H., Wang, J., Burton, E. M., Cohen, L. G., Ajami, N., Wargo, J. A., Daniel, C. R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13234-1 · Cited by 42
Self-citationDiet and Exercise in Cancer Metabolism
Locasale, J. W. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0096 · Cited by 31
Sharma, R., Diwan, B., Sharma, A., & Witkowski, J. M. (2022) · Biogerontology · doi:10.1007/s10522-022-09995-6 · Cited by 33
Live Biotherapeutic Products as Cancer Treatments
Brevi, A., & Zarrinpar, A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2626 · Cited by 33
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Yavuz, B. G., Datar, S. S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M. B., Lee, S. S., Hu, Z. I., Koay, E. J., Cao, H. S. T., Jalal, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15194875 · Cited by 34
Self-citationGut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 33
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 39
A multi-glycomic platform for the analysis of food carbohydrates
Couture, G., Cheang, S. E., Suarez, C., Chen, Y., Bacalzo, N. P., Jiang, J., Weng, C.-Y., Stacy, A., Castillo, J. J., Delannoy-Bruno, O., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-01017-8 · Cited by 30
Design of probiotic delivery systems and their therapeutic effects on targeted tissues
Xu, C., Guo, J., Chang, B., Zhang, Y., Tan, Z., Tian, Z., Duan, X., Ma, J., Jiang, Z., & Hou, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.037 · Cited by 35
Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions
Cote, A. L., Munger, C. J., & Ringel, A. E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115234 · Cited by 29
Hersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy
Shelkey, E., Oommen, D., Stirling, E. R., Soto‐Pantoja, D. R., Cook, K. L., Lu, Y., Votanopoulos, K. I., & Söker, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-13930-7 · Cited by 31
Maesaka, K., Sakamori, R., Yamada, R., Doi, A., Tahata, Y., Ohkawa, K., Oshita, M., Miyazaki, M., Yakushijin, T., Nozaki, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281459 · Cited by 30
Hwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 29
Recent Advances in Molecular and Genetic Research on Uveal Melanoma
Fuentes-Rodriguez, A., Mitchell, A., Guérin, S. L., & Landreville, S. (2024) · Cells · doi:10.3390/cells13121023 · Cited by 34
Wang, M., Liu, Y., Li, Y., Lü, T., Wang, M., Cheng, Z., Chen, L., Wen, T., Pan, M., & Hu, G. (2024) · Advanced Science · doi:10.1002/advs.202405845 · Cited by 41
Somodi, C., Dóra, D., Horváth, M., Szegvári, G., & Lohinai, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06586-0 · Cited by 40
Takada, K., Buti, S., Bersanelli, M., Shimokawa, M., Takamori, S., Matsubara, T., Takenaka, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.002 · Cited by 32
Microbial mechanisms to improve immune checkpoint blockade responsiveness
Griffin, M. E., & Hang, H. C. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100818 · Cited by 31
Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
Zhou, P., Hu, Y., Wang, X., Shen, L., Liao, X., Zhu, Y., Yu, J., Zhao, F., Zhou, Y., Shen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877939 · Cited by 31
Self-citationThe impact of the microbiome in cancer: Targeting metabolism of cancer cells and host
Huang, J., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029033 · Cited by 28
Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 31
Lou, J., Cui, S., Li, J., Jin, G., Fan, Y., & Huang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1279680 · Cited by 32
Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., Palma, E. D., Cerbone, L., Grosso, F., Vecchia, M. L., Bona, E., et al. (2025) · Nutrients · doi:10.3390/nu17172898 · Cited by 30
Knisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 32
Self-citationFeng, X., Li, Z., Guo, W., & Hu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1087755 · Cited by 28
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma
Witt, R. G., Cass, S. H., Tran, T., Damania, A. V., Nelson, E. E., Sirmans, E., Burton, E. M., Chelvanambi, M., Johnson, S. B., Tawbi, H. A., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2955 · Cited by 28
Self-citationImproving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
Wei, J., Hu, M., & Du, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845923 · Cited by 34
Dietary modulation of the gut microbiome as an immunoregulatory intervention
Matson, V. Z., & Gajewski, T. F. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.014 · Cited by 28
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 33
Namikawa, K., Ito, T., Yoshikawa, S., Yoshino, K., Kiniwa, Y., Ohe, S., Isei, T., Takenouchi, T., Kato, H., Mizuhashi, S., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6438 · Cited by 27
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Messaoudene, M., Ferreira, S., Saint-Lu, N., Ponce, M., Truntzer, C., Boidot, R., Le Bescop, C., Loppinet, T., Corbel, T., Féger, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52373-8 · Cited by 24
Microbiome Modulation for the Treatment of Solid Neoplasms
Barragán-Carrillo, R., Zengin, Z. B., & Pal, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00374 · Cited by 33
Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Morder, K. M., Nguyen, M., Wilfahrt, D. N., Dahmani, Z. L., Burr, A. B. P., Xie, B., Morikone, M., Nieves-Rosado, H. M., Gunn, W. G., Hurd, D. E., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0247 · Cited by 30
Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover
Schemczssen-Graeff, Z., & Pileggi, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.921972 · Cited by 30
Measuring and modelling tumour heterogeneity across scales
Beeghly, G. F., Shimpi, A. A., Riter, R. N., & Fischbach, C. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00087-9 · Cited by 30
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
Self-citationLiu, N., Yan, M., Lü, C., Tao, Q., Wu, J., Zhou, Z., Chen, J., Chen, X., & Peng, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122815 · Cited by 25
Scher, J. U., Nayak, R. R., & Clemente, J. C. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225735 · Cited by 25
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 27
Acquired resistance to immunotherapy in solid tumors
Verdys, P., Johansen, A. Z., Gupta, A. K., Presti, M., Dionisio, E., Madsen, D. H., Fontecedro, A. C., & Donia, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.010 · Cited by 32
Obesity–cancer axis crosstalk: Molecular insights and therapeutic approaches
Rakib, A., Mamun, M. A. A., Mandal, M., Sinha, P., & Singh, U. P. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.029 · Cited by 31
New insights into gut microbiota–prostate cancer crosstalk
Laaraj, J., Lachance, G., Bergeron, A., Fradet, Y., Robitaille, K., & Fradet, V. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.015 · Cited by 27
Wang, L., Jiang, W., Yang, M., Danzeng, Q., Liu, S., & Cui, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02275-z · Cited by 29
Self-citationGut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
Schmid, S., Minnella, E. M., Pilon, Y., Rokah, M., Rayes, R. F., Najmeh, S., Cools‐Lartigue, J., Ferri, L. E., Mulder, D. S., Sirois, C., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.05.004 · Cited by 25
Li, Y., Zhang, D., Wang, M., Jiang, H., Feng, C., & Li, Y. (2023) · iMeta · doi:10.1002/imt2.102 · Cited by 22
Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., & Zhu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190850 · Cited by 26
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
Newman, N. K., Macovsky, M. S., Rodrigues, R. R., Bruce, A. M., Pederson, J. W., Padiadpu, J., Shan, J., Williams, J., Patil, S. S., Dzutsev, A., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00960-w · Cited by 28
Self-citationRahman, M. M., Siddique, N., Hasnat, S., Rahman, M. T., Rahman, M., Alam, M., Das, Z. C., Islam, T., & Hoque, M. N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0316270 · Cited by 22
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
Wang, Y., Zheng, Y., Kuang, L., Yang, K., Xie, J., Liu, X., Shen, S., Li, X., Wu, S., Yang, Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01375-5 · Cited by 27
Gut microbiota and immunosenescence in cancer
Xu, Y., He, C., Xi, Y., Zhang, Y., & Bai, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.004 · Cited by 24
Zhou, L., Yin, X., Fang, B., He, J., Zhan, J., Zhang, X., & Wang, R. (2024) · Microorganisms · doi:10.3390/microorganisms12030493 · Cited by 28
Self-citationZhao, S., Lu, Z., Zhao, F., Tang, S., Zhang, L., & Feng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1538969 · Cited by 32
Gut modulation to regulate NF-κB in colorectal and gastric cancer therapy and inflammation
Kearns, R. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04118-9 · Cited by 26
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
Microbiome modulation of tumorigenesis and immune responses
Chen, Y., Fang, Y., Lyu, Z., Tian, Y., Niu, S., Li, Y.-R., & Yang, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01208-9 · Cited by 30
Yue, Y., & Hu, Y. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac310 · Cited by 23
Anderson, K. G., Braun, D. A., Buqué, A., Gitto, S. B., Guerriero, J. L., Horton, B. L., Keenan, B. P., Kim, T. S., Overacre-Delgoffe, A. E., Ruella, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006533 · Cited by 24
Aggarwal, H., Gautam, J., Kumari, D., Gupta, S. K., Bajpai, S., Chaturvedi, K., Kumar, Y., & Dikshit, M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119643 · Cited by 24
Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
The microbiome as a therapeutic co-driver in melanoma immuno-oncology
Bautista, J., Chávez, J. A. V., Larco, D. S. B., Martín-Aguilera, R., & López‐Cortés, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1673880 · Cited by 28
Aldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
Cancer ecosystems: A dynamic interplay across scales
Quail, D. F., & Joyce, J. A. (2026) · Cell · doi:10.1016/j.cell.2026.03.003 · Cited by 30
The cure from within? a review of the microbiome and diet in melanoma
Kumar, P. R., Brazel, D., DeRogatis, J. M., Goldstein, J. B., Whiteson, K., Chow, W. A., Tinoco, R., & Moyers, J. T. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10029-3 · Cited by 25
Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 24
Diet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
Insights of probiotics as an alternative medicine for cancer therapy, mechanism, and applications
Mukherjee, S., Kumar, D., & Guha, D. (2024) · Medicine in Microecology · doi:10.1016/j.medmic.2024.100111 · Cited by 25
The immunomodulatory effects of vitamins in cancer
Munteanu, C., Mârza, S. M., & Papuc, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1464329 · Cited by 24
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
Zuo, S., Huang, Y., & Zou, J. (2024) · IUBMB Life · doi:10.1002/iub.2908 · Cited by 23
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
Self-citationChen, J., Zhang, L., Jiao, Y., Lu, X., Zhang, N., Li, X., Zheng, S., Li, B., Liu, F., & Zuo, P. (2025) · Nutrients · doi:10.3390/nu17152537 · Cited by 23
Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics
Zitvogel, L., Derosa, L., & Kroemer, G. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.004 · Cited by 20
Gut microbiota – a double-edged sword in cancer immunotherapy
Andrews, M. C., & Vasanthakumar, A. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.003 · Cited by 20
Self-citationGut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
Pizzutilo, E. G., Romanò, R., Roazzi, L., Agostara, A. G., Oresti, S., Zeppellini, A., Giannetta, L. G., Cerea, G., Signorelli, D., Siena, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0161 · Cited by 20
Hahn, A. W., Venkatesh, N., Msaouel, P., & McQuade, J. L. (2023) · Cells · doi:10.3390/cells12212551 · Cited by 23
Self-citation
Metadata
- Authors
- Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., Wong, M. C., Morad, G., Rodgers, T., Badger, J. H., Helmink, B. A., Andrews, M. C., Rodrigues, R. R., Morgun, A., Kim, Y. S., Roszik, J., Hoffman, K. L., Zheng, J., Zhou, Y., Medik, Y. B., Kahn, L. M., Johnson, S., Hudgens, C. W., Wani, K., Gaudreau, P.-O., Harris, A. L., Jamal, M. A., Baruch, E. N., Perez-Guijarro, E., Day, C.-P., Merlino, G., Pazdrak, B., Lochmann, B. S., Szczepaniak-Sloane, R. A., Arora, R., Anderson, J., Zobniw, C. M., Posada, E., Sirmans, E., Simon, J., Haydu, L. E., Burton, E. M., Wang, L., Dang, M., Clise-Dwyer, K., Schneider, S., Chapman, T., Anang, N.-A. A. S., Duncan, S., Toker, J., Malke, J. C., Glitza, I. C., Amaria, R. N., Tawbi, H. A., Diab, A., Wong, M. K., Patel, S. P., Woodman, S. E., Davies, M. A., Ross, M. I., Gershenwald, J. E., Lee, J. E., Hwu, P., Jensen, V., Samuels, Y., Straussman, R., Ajami, N. J., Nelson, K. C., Nezi, L., Petrosino, J. F., Futreal, P. A., Lazar, A. J., Hu, J., Jenq, R. R., Tetzlaff, M. T., Yan, Y., Garrett, W. S., Huttenhower, C., Sharma, P., Watowich, S. S., Allison, J. P., Cohen, L., Trinchieri, G., Daniel, C. R., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
- Frederick National Laboratory for Cancer Research (US)
- Oregon State University (US)
- Baylor College of Medicine (US)
- Queen's University (CA)
- The University of Texas Health Science Center at Houston (US)
- Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Harvard University (US)
- Weizmann Institute of Science (IL)
- European Institute of Oncology (IT)
- Columbia University (US)
- University of California, San Francisco (US)
- Broad Institute (US)
- Corresponding author
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Cogdill, Alexandria P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- ORCID
- Spencer, Christine N.
- McQuade, Jennifer L.
- Gopalakrishnan, Vancheswaran
- McCulloch, John A.
- Vetizou, Marie
- Cogdill, Alexandria P.
- Khan, Md A. Wadud
- Zhang, Xiaotao
- White, Michael G.
- Peterson, Christine B.
- Wong, Matthew C.
- Morad, Golnaz
- Rodgers, Theresa
- Badger, Jonathan H.
- Helmink, Beth A.
- Andrews, Miles C.
- Rodrigues, Richard R.
- Morgun, Andrey
- Kim, Young S.
- Roszik, Jason
- Hoffman, Kristi L.
- Zhou, Yifan
- Medik, Yusra B.
- Kahn, Laura M.
- Johnson, Sarah
- Hudgens, Courtney W.
- Wani, Khalida
- Gaudreau, Pierre-Olivier
- Harris, Angela L.
- Jamal, Mohamed A.
- Baruch, Erez N.
- Perez-Guijarro, Eva
- Day, Chi-Ping
- Merlino, Glenn
- Pazdrak, Barbara
- Lochmann, Brooke S.
- Arora, Reetakshi
- Anderson, Jaime
- Zobniw, Chrystia M.
- Simon, Julie
- Haydu, Lauren E.
- Burton, Elizabeth M.
- Wang, Linghua
- Dang, Minghao
- Clise-Dwyer, Karen
- Schneider, Sarah
- Anang, Nana-Ama A. S.
- Toker, Joseph
- Malke, Jared C.
- Glitza, Isabella C.
- Amaria, Rodabe N.
- Tawbi, Hussein A.
- Diab, Adi
- Wong, Michael K.
- Patel, Sapna P.
- Woodman, Scott E.
- Davies, Michael A.
- Ross, Merrick I.
- Gershenwald, Jeffrey E.
- Lee, Jeffrey E.
- Hwu, Patrick
- Jensen, Vanessa
- Samuels, Yardena
- Straussman, Ravid
- Ajami, Nadim J.
- Nelson, Kelly C.
- Nezi, Luigi
- Petrosino, Joseph F.
- Futreal, P. Andrew
- Lazar, Alexander J.
- Hu, Jianhua
- Jenq, Robert R.
- Tetzlaff, Michael T.
- Yan, Yan
- Garrett, Wendy S.
- Huttenhower, Curtis
- Sharma, Padmanee
- Watowich, Stephanie S.
- Allison, James P.
- Cohen, Lorenzo
- Trinchieri, Giorgio
- Daniel, Carrie R.
- Wargo, Jennifer A.
- Venue
- Science
- Published
- 2021-12-24
- Volume
- 374
- Issue
- 6575
- Pages
- 1632-1640
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8970537
- OpenAlex
- W4200001874
- Cited by
- 966
- References
- 70
- Citations by year
- 2026: 236 · 2025: 216 · 2024: 172 · 2023: 212 · 2022: 130
- FWCI
- 46.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research UK (27140)
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P50CA221703, R01CA219896, F32CA260769, U54CA224070, T32CA009599, R25CA203650, P30CA016672, P30CA013696)
- National Institute of Allergy and Infectious Diseases (R56AI109294, R01AI133822, R01AI143886, R01AI109294)
- National Institute of Environmental Health Sciences (P30ES030285)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- dietary fiber, probiotics, gut microbiota, melanoma, immune checkpoint blockade, anti-PD-1 therapy, treatment response, progression-free survival, fecal microbiota, tumor microenvironment, interferon-gamma, cytotoxic T lymphocytes, low-fiber diet
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Progression-Free Survival, Immune Checkpoint Inhibitors, Animals, Dietary Fiber, Fatty Acids, Volatile, Feces, Female, Humans, Immunotherapy, Male, Melanoma, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cohort Studies, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.